Compass Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our corporate headquarters is located at 80 Guest Street, Boston, Massachusetts, and consists of 19,112 square feet of office space and laboratory space pursuant to a sublease agreement that expires in May 2025. In September 2024, we signed a new lease on our existing facility, effective May 2025, extending the term six years to May 2031 and expanding the space to 29,836 square feet. We believe that these facilities are adequate for our current needs and that suitable additional or substitute space will be available in the future if needed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.